Home 禄 Business 禄 Manufacturing
Human Genome deal?
Source: Agencies |
July 16, 2012, Monday
|
Print Edition
Print Edition
GLAXOSMITHKLINE is holding talks to buy Human Genome Sciences for some US$2.6 billion, after pursuing the US biotech firm for three months, sources said yesterday.
Human Genome, which rejected a US$13-a-share offer in April from GlaxoSmithKline, its long-time partner, has come under pressure from investors to try and strike a deal with the British drugmaker in the absence of any alternative bids. The US company - an early pioneer of gene-based drug discovery - has set itself a deadline that ends today for finding higher bids.
Human Genome, which rejected a US$13-a-share offer in April from GlaxoSmithKline, its long-time partner, has come under pressure from investors to try and strike a deal with the British drugmaker in the absence of any alternative bids. The US company - an early pioneer of gene-based drug discovery - has set itself a deadline that ends today for finding higher bids.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
